Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Ramirez appointed FTC chair; budget sequester slows FDA travel, training; ChromaDex divests BluScience brand; Omega Protein buys whey firm; Vitamin Shoppe absorbs integration costs; Vitacost trims net loss in Q4; chemical regulation champion Lautenberg to retire; USANA expands in China.

You may also be interested in...



Investor Taunts Omega Protein, Suggests Ripe Conditions For Sale

Wynnefield Capital, in an SEC filing, includes a letter it sent to Omega Protein noting M&A activity in the fish product market creates promising conditions for the firm’s sale. The group also makes candid observations about its lack of faith in Omega Protein’s management.

Investor Taunts Omega Protein, Suggests Ripe Conditions For Sale

Wynnefield Capital, in an SEC filing, includes a letter it sent to Omega Protein noting M&A activity in the fish product market creates promising conditions for the firm’s sale. The group also makes candid observations about its lack of faith in Omega Protein’s management.

Industry News Roundup

‘Heal yourself’ claim nicked by FDA; Urban Moonshine’s error of omission; new tech needs old school substantiation; O2 plans big for InboxFitness; Migranade sprouts spray division; ChromaDex cashes in NeutriSci shares; GoodSense sponsors runDisney; Walgreens joins flu tracking crowd; Qualitas algal omega-3 reaches market; Islet cooks cannabidoil in business plan; and Food Advisory Committee candidates sought.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel